Roche Diabetes Care Announces National Infusion Site Awareness Week, Aug. 30-Sept. 5, to Foster Better Diabetes Management and Education
Roche Diabetes Care, makers of the ACCU-CHEK® portfolio of diabetes management products and services, is pleased to announce the inaugural National Infusion Site Awareness Week, Aug. 30-Sept. 5. Roche made the announcement during the 37th annual American Association of Diabetes Educators (AADE) conference to highlight the important role that certified diabetes educators and other health care professionals play in promoting better site management for the 400,000 people in the United States with Type 1 diabetes who use an insulin pump.
For people with diabetes, the infusion site is where an insulin pump’s plastic cannula or steel needle is placed under the user’s skin to administer insulin. Infusion site management is the practice of choosing a site, cleaning and preparing it, properly inserting a cannula or needle, monitoring insulin flow and then regularly rotating the insertion site to avoid infection. In most cases, this site must be changed every one-three days and the same site must not be reused for about two weeks or until the site has fully healed.
Roche is creating the week to increase understanding and education about proper infusion site management—and complications that can result from poor site management such as infection, poor insulin delivery and tissue or skin damage. A 2007 study in the American Diabetes Association journal Diabetes Care reported that some adult patients experience as many as 12 issues of irritation or infection a year because of poor site maintenance. The authors concluded that “efforts to minimize the risk of irritation, scarring, and infection should include strict adherence to proper infusion site preparation, catheter insertion, and site rotation.”1
“Roche Diabetes Care is sponsoring the first National Infusion Site Awareness Week to raise awareness of the unique challenges faced by users of insulin infusion pumps,” said Luc Vierstraete, senior vice president and general manager, Roche Diabetes Care North America. “Proper infusion site management ensures better blood glucose management as well as fewer complications. This correlation between site management and better health outcomes is why increased education is critical to foster better diabetes management.”
To help increase education, Roche is distributing National Infusion Site Awareness Week kits to certified diabetes educators throughout the United States. These kits include an educational DVD explaining proper site maintenance, press promotional materials, fact sheets to help facilitate discussions and collateral such as buttons, temporary tattoos and a logo. Diabetes educators can receive the kits by signing up for one at Roche’s booth (3137) during the AADE conference. Information can also be found at www.infusionsitemanagement.com.
“Proper infusion site management is a key component of successful diabetes management,” said Stuart Bootle, MB ChB, an international expert about diabetes management. “As a person with Type 1 diabetes who has worn an insulin pump for more than 12 years, I know firsthand the benefits and challenges of wearing a pump. The education and awareness generated by the inaugural National Infusion Site Awareness Week will help people with diabetes to develop life-long practices that ensure better health outcomes with fewer complications.”
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients’ condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management—from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems. For more information, please visit accu-chek.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.
All trademarks used or mentioned in this release are protected by law.
For further information, please contact:
Todd A. Siesky
Public Relations Manager
Roche Diabetes Care